Cargando…

How is overall survival assessed in randomised clinical trials in cancer and are subsequent treatment lines considered? A systematic review

BACKGROUND: Overall survival is the “gold standard” endpoint in cancer clinical trials. It plays a key role in determining the clinical- and cost-effectiveness of a new intervention and whether it is recommended for use in standard of care. The assessment of overall survival usually requires trial p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Royle, Kara-Louise, Meads, David, Visser-Rogers, Jennifer K., White, Ian R., Cairns, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626781/ https://www.ncbi.nlm.nih.gov/pubmed/37926806 http://dx.doi.org/10.1186/s13063-023-07730-1

Ejemplares similares

The development and validation of prognostic models for overall survival in the presence of missing data in the training dataset: a strategy with a detailed example
por: Royle, Kara-Louise, et al.
Publicado: (2021)

Overall and disease‐specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer
por: Rigter, Lisanne S., et al.
Publicado: (2018)

Subsequent anti-VEGF therapy after first-line anti-EGFR therapy improved overall survival of patients with metastatic colorectal cancer
por: Qiu, Tianzhu, et al.
Publicado: (2018)

The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial
por: Cook, Gordon, et al.
Publicado: (2019)

Estimation of Overall Survival with Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE Study
por: Koroki, Yosuke, et al.
Publicado: (2022)

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial
por: Coulson, Amy Beth, et al.
Publicado: (2022)

Association of perioperative adverse events with subsequent therapy and overall survival in patients with WHO grade III and IV gliomas
por: Weber, Lorenz, et al.
Publicado: (2022)

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study
por: Royle, Kara‐Louise, et al.
Publicado: (2018)

Incidence and Overall Survival of Malignant Ameloblastoma
por: Rizzitelli, Alexandra, et al.
Publicado: (2015)

Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer
por: Liu, Liya, et al.
Publicado: (2015)

Osteosarcoma of the Pelvis: Clinical Presentation and Overall Survival
por: Brown, Jeffrey Mark, et al.
Publicado: (2021)

What are patients’ experiences of discontinuing clozapine and how does this impact their views on subsequent treatment?
por: Southern, Jennifer, et al.
Publicado: (2023)

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?
por: Forsythe, Anna, et al.
Publicado: (2018)

Higher overall survival in metastatic pancreatic cancer: the impact of where and how treatment is delivered
por: Usón, Pedro Luiz Serrano, et al.
Publicado: (2015)

The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?
por: Lux, Michael Patrick, et al.
Publicado: (2021)

Impact of early palliative care on overall survival of patients with metastatic upper gastrointestinal cancers treated with first-line chemotherapy: a randomised phase III trial
por: Hutt, Emilie, et al.
Publicado: (2018)

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial
por: Royle, Kara-Louise, et al.
Publicado: (2022)

Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
por: Beauchemin, Catherine, et al.
Publicado: (2014)

Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma
por: Hsiao, Pojen, et al.
Publicado: (2019)

LINE-1 hypomethylation in human hepatocellular carcinomas correlates with shorter overall survival and CIMP phenotype
por: Anwar, Sumadi Lukman, et al.
Publicado: (2019)

Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer
por: Whitaker, Kristen D., et al.
Publicado: (2022)

Surrogate endpoints for overall survival in randomised controlled trials of localised osteosarcoma: A meta-analytic evaluation
por: Tanaka, Kazuhiro, et al.
Publicado: (2020)

Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
por: Heaney, Jennifer L. J., et al.
Publicado: (2018)

Correction: Impact of early palliative care on overall survival of patients with metastatic upper gastrointestinal cancers treated with first-line chemotherapy: a randomised phase III trial
Publicado: (2019)

Sextual Intercourse: Considering Social–Cognitive Predictors and Subsequent Outcomes of Sexting Behavior in Adulthood
por: Brodie, Zara P., et al.
Publicado: (2019)

The impact of increasing dose on overall survival in prostate cancer
por: Hall, Matthew D., et al.
Publicado: (2015)

Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study
por: Ouwens, Mario, et al.
Publicado: (2021)

Do breast implants after a mastectomy affect subsequent prognosis and survival?
por: Brinton, Louise A
Publicado: (2005)

The impact of previous cancer on overall survival of bladder cancer patients and the establishment of nomogram for overall survival prediction
por: Wang, Zhengquan, et al.
Publicado: (2020)

Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma
por: Amdahl, Jordan, et al.
Publicado: (2016)

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
por: Tanguy, Marie-Laure, et al.
Publicado: (2018)

Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine
por: Tsimberidou, Apostolia-Maria, et al.
Publicado: (2019)

Considering an Approach for Assessing the Relevance of Tattoo-associated Health Risk from an Overall Toxicological Perspective
por: KWON, Yongbum, et al.
Publicado: (2018)

Associations Between Sexual Orientation and Overall and Site-Specific Diagnosis of Cancer: Evidence From Two National Patient Surveys in England
por: Saunders, Catherine L., et al.
Publicado: (2017)

Conditioning with melphalan 200 mg/m(2) and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care
por: Afram, Gabriel, et al.
Publicado: (2022)

Study group considers how to preserve data
Publicado: (2009)

Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer
por: Varkaris, Andreas, et al.
Publicado: (2019)

Chronic Obstructive Pulmonary Disease and Subsequent Overall and Lung Cancer Mortality in Low-Income Adults
por: Aldrich, Melinda C., et al.
Publicado: (2015)

Is there hope in improving 5-year overall survival?—review of 5-year overall survival data from KEYNOTE-001
por: Akingbemi, Wisdom, et al.
Publicado: (2020)

Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma
por: Horvat, Mateja, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_pmuknfvku59polasf7ubh7oa6j